New York City’s subway system experienced its worst service summer in years, with significant delays and disruptions frustrating commuters. However, MTA Chief Executive, John Smith, suggested a contrasting perspective, asserting that it was ‘one of the best’ summers for the subway in terms of ridership recovery and infrastructure upgrades. While on-the-ground complaints surged, Smith emphasized improvements behind the scenes, such as increased maintenance efforts and technological upgrades intended to future-proof the system. Critics, however, point to the visible impacts on daily commuters, questioning the agency’s measures and communication effectiveness. The dissonance between public experience and official statements highlights challenges facing the MTA as it strives to balance immediate commuter satisfaction with long-term projects. This situation underlines a larger narrative about the NYC subway’s struggle to modernize amid increasing demands. As the city moves into fall, all eyes are on the MTA’s strategies to mitigate these issues and improve daily experiences for its riders.
New York PostNew data shows CLYM116 reduces key IgA nephropathy biomarkers by ~70%, supporting a 12-week dosing regimen
October 24, 2026
New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%.